Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients

Shinde, Prajakta; Melinkeri, Sameer; Santra, Manas Kumar; Kale, Vaijayanti; Limaye, Lalita

doi:10.3389/fimmu.2019.01079

Cited by 8 publications

(8 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DC vaccines utilizing DCs from patients to activate immune responses have been used in clinical practice, and immunogenicity determines DC vaccines’ efficacy. Inspired by the function of CCL19-CCR7, research finds that monocyte-derived DCs have a lower transcript and protein level of CCR7, leading to migration dysfunction [ 26 ]. By contrast, hematopoietic stem cell-derived DCs are preferable sources of DC vaccine, as stem cell-derived DCs from MM patients show similarities in cell yield, morphology, and phenotype compared to healthy donors.…”

Section: Main Textmentioning

confidence: 99%

See 1 more Smart Citation

Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)

Du,

Lin,

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

Background The incidence of multiple myeloma (MM), a type of blood cancer affecting monoclonal plasma cells, is rising. Although new drugs and therapies have improved patient outcomes, MM remains incurable. Recent studies have highlighted the crucial role of the chemokine network in MM’s pathological mechanism. Gaining a better understanding of this network and creating an overview of chemokines in MM could aid in identifying potential biomarkers and developing new therapeutic strategies and targets. Purpose To summarize the complicated role of chemokines in MM, discuss their potential as biomarkers, and introduce several treatments based on chemokines. Methods Pubmed, Web of Science, ICTRP, and Clinical Trials were searched for articles and research related to chemokines. Publications published within the last 5 years are selected. Results Malignant cells can utilize chemokines, including CCL2, CCL3, CCL5, CXCL7, CXCL8, CXCL12, and CXCL13 to evade apoptosis triggered by immune cells or medication, escape from bone marrow and escalate bone lesions. Other chemokines, including CXCL4, CCL19, and CXCL10, may aid in recruiting immune cells, increasing their cytotoxicity against cancer cells, and inducing apoptosis of malignant cells. Conclusion Utilizing anti-tumor chemokines or blocking pro-tumor chemokines may provide new therapeutic strategies for managing MM. Inspired by developed CXCR4 antagonists, including plerixafor, ulocuplumab, and motixafortide, more small molecular antagonists or antibodies for pro-tumor chemokine ligands and their receptors can be developed and used in clinical practice. Along with inhibiting pro-tumor chemokines, studies suggest combining chemokines with chimeric antigen receptor (CAR)-T therapy is promising and efficient.

show abstract

Section: Main Textmentioning

confidence: 99%

“…SC-DCs with superior migration than Mo-DCs are potential candidates for cancer vaccines. CAR-T cell immunotherapy DC vaccine [ 16 , 26 ] CXCL4 (PF-4) CXCR3 Former research suggests PF-4 can induce MM cell apoptosis by upregulating SOCS3 expression to regress STAT3. A lower serum level of PF-4 indicates poor overall survival.…”

Section: Main Textmentioning

confidence: 99%

Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)

Du,

Lin,

et al. 2024

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…CD34+ Hematopoietic Stem Progenitor Cells (HSPC) can be used to synthesize DCs in large amounts ex vivo. This CD34+ is superior to MoDCs in that it stimulates a more potent T-cell immune response against cancer, and these are produced by upregulating the expression of tumor necrosis factor-relevant apoptosis-stimulating ligand and enhancing cytotoxicity [45,46]. Derivation of strong CD34+ was typically successfully achieved in a cytokine milieu but it differs as compared to MoDC derivation.…”

Section: Vaccination With Ex-vivo Pulsed Dendritic Cells (Dc) and The...mentioning

confidence: 99%

Comparitive Study of Dendritic Cell Vaccine Preparation With Presence and Absence of Malpighia Emarginata Fruit Extract Using Tumor Rna Transfection Method: A Promising Approach for Prostate Cancer

2023

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Acerola (Malpighia emarginata DC) is the richest natural source of ascorbic acid and also contains a plethora of phytonutrients such as flavonoids, anthocyanins, carotenoids, and phenolics. By using the fruits of Malpighia emarginata, are used for the treatment of cancer by inducing effective anti-tumor immunity through dendritic cells. Dendritic cells (DC) are the heterogeneous population of antigen-presenting cells that invade tumors. They play an important role in the priming and maintenance of local immunity, and their major function is diminished by some factors encountered in the local environment. For the success of cancer immunotherapy, adequate tumor-specific antigens play a very important role in inducing a tumor-specific immune response by effective delivery of these antigens. In this proposal, by using these strategies, mature and immature dendritic cells were obtained in-vitro by adding specific cytokines to monocyte cell culture containing Malpighia emarginata fruit extract in the presence of prostate-specific antigen (PSA), and their results were compared to those obtained without the presence of Malpighia emarginata fruit extract. In the prostate tumor lineage, the RNA is extracted into the cell by electroporation, and the transfection success was measured by immunocytochemistry of the PSA expression level in dendritic cells. For the comparative study of in-vitro RNA transcription, this method allows small tumors to be used for dendritic cell vaccine preparation through the activation of DC by in the presence and absence of Malpighia emarginata fruit extract and it is a promising approach for the treatment of metastatic prostate cancer.

show abstract

“…Alternative sources are being investigated, including the differentiation of DCs from human pluripotent stem cells (hPSCs) [119,156]. Shinde et al compared stem cell-derived DCs from MM patients (MM-SC-DCs) with those from healthy individuals (HD-SC-DCs) [157]. Besides a similar SC-DC yield, both MM-SC-DCs and HD-SC-DCs exhibited a mature DC cell-surface phenotype.…”

Section: A New Upcoming DC Source For Dc-based Immunotherapymentioning

confidence: 99%

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions

Verheye

Melgar

Deschoemaeker

et al. 2022

IJMS

View full text Add to dashboard Cite

Immunotherapeutic approaches, including adoptive cell therapy, revolutionized treatment in multiple myeloma (MM). As dendritic cells (DCs) are professional antigen-presenting cells and key initiators of tumor-specific immune responses, DC-based immunotherapy represents an attractive therapeutic approach in cancer. The past years, various DC-based approaches, using particularly ex-vivo-generated monocyte-derived DCs, have been tested in preclinical and clinical MM studies. However, long-term and durable responses in MM patients were limited, potentially attributed to the source of monocyte-derived DCs and the immunosuppressive bone marrow microenvironment. In this review, we briefly summarize the DC development in the bone marrow niche and the phenotypical and functional characteristics of the major DC subsets. We address the known DC deficiencies in MM and give an overview of the DC-based vaccination protocols that were tested in MM patients. Lastly, we also provide strategies to improve the efficacy of DC vaccines using new, improved DC-based approaches and combination therapies for MM patients.

show abstract

Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients

Cited by 8 publications

References 56 publications

Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)

Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM)

Comparitive Study of Dendritic Cell Vaccine Preparation With Presence and Absence of Malpighia Emarginata Fruit Extract Using Tumor Rna Transfection Method: A Promising Approach for Prostate Cancer

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions

Contact Info

Product

Resources

About